Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year

Simply Wall StDec 14 08:53 ET

Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares

Quiver QuantitativeDec 10 19:16 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Stoke Therapeuticsto Overweight

BenzingaDec 10 08:55 ET

Stoke Therapeutics Analyst Ratings

BenzingaDec 10 08:53 ET · Ratings

Stoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy Rating

TipRanksDec 10 01:06 ET · Ratings

Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsDec 9 14:32 ET · Ratings